Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder

The Pharmacogenomics Journal volume 13, pages 349–353 (2013)Cite this article

Subjects

Abstract

P-glycoprotein (P-gp), an ATP-driven efflux pump in the blood-brain barrier, has a major impact on the delivery of antidepressant drugs in the brain. Genetic variants in the gene ABCB1 encoding for P-gp have inconsistently been associated with adverse effects. In order to resolve these inconsistencies, we conducted a study in a large cohort of patients with major depressive disorder with the aim to unravel the association of ABCB1 variants with adverse effects of antidepressants and in particular with selective serotonin reuptake inhibitors (SSRIs), which display affinity as substrate for P-gp. The Netherlands Study of Depression and Anxiety (NESDA) study was used as a clinical sample. For 424 patients data were available on drug use, side effects. We selected six ABCB1 gene variants (1236T>C, 2677G>T/A, 3435T>C, rs2032583, rs2235040 and rs2235015) and analyzed them for association with adverse drug effects using multinomial regression analysis for both single variants and haplotypes. We found a significant association between the number of SSRI-related adverse drug effects and rs2032583 (P=0.001), rs2235040 (P=0.002) and a haplotype (P=0.002). Moreover, serotonergic effects (sleeplessness, gastrointestinal complaints and sexual effects) were significantly predicted by these variants and haplotype (P=0.002/0.003). We conclude that adverse drug effects with SSRI treatment, in particular serotonergic effects, are predicted by two common polymorphisms of the ABCB1 gene.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chan GN, Bendayan R . Molecular and functional characterization of p-glycoprotein in vitro. Methods Mol Biol 2011; 686: 313–336.

    Article  CAS  PubMed  Google Scholar 

  2. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005; 33: 165–174.

    Article  CAS  PubMed  Google Scholar 

  3. Uhr M, Steckler T, Yassouridis A, Holsboer F . Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380–387.

    Article  CAS  PubMed  Google Scholar 

  4. Uhr M, Grauer MT, Holsboer F . Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003; 54: 840–846.

    Article  CAS  PubMed  Google Scholar 

  5. Weber CC, Kressmann S, Ott M, Fricker G, Muller WE . Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry 2005; 38: 293–300.

    Article  CAS  PubMed  Google Scholar 

  6. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE . Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305: 197–204.

    Article  CAS  PubMed  Google Scholar 

  7. Mihaljevic PA, Bozina N, Sagud M, Rojnic KM, Lovric M . MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1439–1444.

    Article  Google Scholar 

  8. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 398–404.

    Article  CAS  PubMed  Google Scholar 

  9. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR . ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007; 7: 154–179.

    Article  CAS  PubMed  Google Scholar 

  10. Lin KM, Chiu YF, Tsai IJ, Chen CH, Shen WW, Liu SC et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 2011; 21: 163–170.

    CAS  PubMed  Google Scholar 

  11. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy Jr GM . ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 2010; 20: 467–475.

    Article  CAS  PubMed  Google Scholar 

  12. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57: 203–209.

    Article  CAS  PubMed  Google Scholar 

  13. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP . Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 2010; 67: 1110–1113.

    Article  CAS  PubMed  Google Scholar 

  14. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA . A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2: 191–196.

    Article  CAS  PubMed  Google Scholar 

  15. De Luca V, Mundo E, Trakalo J, Wong GW, Kennedy JL . Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania. Pharmacogenomics J 2003; 3: 297–299.

    Article  CAS  PubMed  Google Scholar 

  16. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008; 3: e1872.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, Spinhoven P et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res 2008; 17: 121–140.

    Article  PubMed  Google Scholar 

  18. World Health Organization. ATC/DDD Index 2010; [update 27 October 2009; cited 5 December 2009]. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. Available from: http://www.whocc.no/atcddd, 2011.

  19. Störmer E, von Moltke LL, Perloff MD, Greenblatt DJ . P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol 2001; 41: 708–714.

    Article  PubMed  Google Scholar 

  20. Szabo D, Szabo Jr G, Ocsovszki I, Aszalos A, Molnar J . Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 1999; 139: 115–119.

    Article  CAS  PubMed  Google Scholar 

  21. Wang JS, Zhu HJ, Gibson BB, Markowitz JS, Donovan JL, DeVane CL . Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull 2008; 31: 231–234.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM . Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001; 21: 778–796.

    Article  CAS  PubMed  Google Scholar 

  23. Löscher W, Potschka H . Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005; 76: 22–76.

    Article  PubMed  Google Scholar 

  24. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1–100.

    Article  CAS  PubMed  Google Scholar 

  25. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W et al. Adverse reactions to antidepressants. Br J Psychiatry 2009; 195: 202–210.

    Article  PubMed  Google Scholar 

  26. Dong C, Wong ML, Licinio J . Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14: 1105–1118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Qian W, Homma M, Itagaki F, Tachikawa H, Kawanishi Y, Mizukami K et al. MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol Pharm Bull 2006; 29: 2446–2450.

    Article  CAS  PubMed  Google Scholar 

  28. Boomsma DI, Willemsen G, Sullivan PF, Heutink P, Meijer P, Sondervan D et al. Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. Eur J Hum Genet 2008; 16: 335–342.

    Article  CAS  PubMed  Google Scholar 

  29. Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry 2009; 14: 359–375.

    Article  CAS  PubMed  Google Scholar 

  30. Marchini J, Howie B . Comparing algorithms for genotype imputation. Am J Hum Genet 2008; 83: 535–539.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Barak Y, Swartz M, Levy D, Weizman R . Age-related differences in the side effect profile of citalopram. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 545–548.

    Article  CAS  PubMed  Google Scholar 

  32. Sramek JJ, Cutler NR . The Impact of Gender on Antidepressants. Curr Top Behav Neurosci 2011; 8: 231–249.

    Article  CAS  PubMed  Google Scholar 

  33. Stephens M, Scheet P . Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005; 76: 449–462.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Stephens M, Smith NJ, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978–989.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG . Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002; 53: 79–91.

    Article  PubMed  Google Scholar 

  36. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2011; 21: 152–161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Woodahl EL, Ho RJ . The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004; 5: 11–19.

    Article  CAS  PubMed  Google Scholar 

  38. Holtzman CW, Wiggins BS, Spinler SA . Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006; 26: 1601–1607.

    Article  CAS  PubMed  Google Scholar 

  39. Weiss J, Haefeli WE . Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol 2010; 280: 219–279.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Funding support was provided by Center for Medical systems Biology (NWO Genomics), the Geestkracht program of ZonMW (10-000-1002) and institutes involved in NESDA (VU University Medical Center, Leiden University Medical Center, GGZ InGeest, Rivierduinen, University Medical Center Groningen, GGZ Lentis, GGZ Friesland, GGZ Drenthe). The genotyping of the samples was provided through the Genetic Association Information Network (GAIN).

Author information

Authors and Affiliations

  1. University Center of Psychiatry, University Medical Center Groningen, Groningen, The Netherlands

    O L de Klerk, F J Bosker, J A den Boer, R Bruggeman & B W Penninx

  2. GGZ Drenthe, Ass, en, The Netherlands

    O L de Klerk

  3. Department of Epidemiology, Unit of Genetic Epidemiology and Bioinformatics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    I M Nolte & H Snieder

  4. VU University Medical Center, Amsterdam, The Netherlands

    P M Bet & B W Penninx

  5. Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands

    W J Hoogendijk

  6. Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands

    B W Penninx

Authors
  1. O L de Klerk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I M Nolte
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P M Bet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F J Bosker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Snieder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J A den Boer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Bruggeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W J Hoogendijk
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B W Penninx
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O L de Klerk.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

de Klerk, O., Nolte, I., Bet, P. et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J 13, 349–353 (2013). https://doi.org/10.1038/tpj.2012.16

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2012.16

Keywords

  • ABCB1
  • adverse drug reactions
  • major depressive disorder
  • P-glycoprotein
  • single-nucleotide polymorphism
  • SSRI

This article is cited by

Search

Advanced search

Quick links